Vitamin E succinate inhibits NF-κB and prevents the development of a metastatic phenotype in prostate cancer cells: Implications for chemoprevention

Prostate

Volumn 67, Issue 6, 2007, Pages 582-590

  Crispen, Paul L ^a   Uzzo, Robert G ^a   Golovine, Konstantin ^a   Makhov, Peter ^a   Pollack, Alan ^a   Horwitz, Eric M ^a   Greenberg, Richard E ^a   Kolenko, Vladimir M ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Adhesion; AP 1; Apoptosis; Cytokines

Indexed keywords

ALPHA TOCOPHEROL SUCCINATE; CYTOKINE; FIBRONECTIN; GLYCOPROTEIN GP 130; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; INTERLEUKIN 8; PROPIDIUM IODIDE; PROTEIN BCL XL; TRANSCRIPTION FACTOR AP 1; VASCULOTROPIN; X LINKED INHIBITOR OF APOPTOSIS;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER PREVENTION; CELL ADHESION; CELL VIABILITY; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INHIBITION KINETICS; MALE; METASTASIS; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DETERMINATION; PROTEIN EXPRESSION; STAINING;

ANTINEOPLASTIC AGENTS; CELL ADHESION; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MALE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NF-KAPPA B; PHENOTYPE; PROSTATIC NEOPLASMS; TRANSCRIPTION FACTOR AP-1; TUMOR MARKERS, BIOLOGICAL; VITAMIN E;

EID: 34247571820     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20468     Document Type: Article

References (41)

1. Edwards BK, Brown ML, Wingo PA, Howe HL, Ward E, Ries LA, et al. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 2005;97(19):1407-1427.
2. Heinonen OP, Albanes D, Virtamo J, Taylor PR, Huttunen JK, Hartman AM, et al. Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: Incidence and mortality in a controlled trial. J Natl Cancer Inst 1998;90(6):440-446.
3. Parnes HL, House MG, Kagan J, Kausal DJ, Lieberman R. Prostate cancer chemoprevention agent development: The National Cancer Institute, Division of Cancer Prevention portfolio. J Urol 2004;171(2 Pt 2):S68-74; discussion S75.
4. Steele VE. Current mechanistic approaches to the chemoprevention of cancer. J Biochem Mol Biol 2003;36(1):78-81.
5. Weinstein SJ, Wright ME, Pietinen P, King I, Tan C, Taylor PR, et al. Serum alpha-tocopherol and gamma-tocopherol in relation to prostate cancer risk in a prospective study. J Natl Cancer Inst 2005;97(5):396-399.
6. Prasad KN, Edwards-Prasad J. Effects of tocopherol (vitamin E) acid succinate on morphological alterations and growth inhibition in melanoma cells in culture. Cancer Res 1982;42(2): 550-555.
7. Israel K, Yu W, Sanders BG, Kline K. Vitamin E succinate induces apoptosis in human prostate cancer cells: Role for Fas in vitamin E succinate-triggered apoptosis. Nutr Cancer 2000;36(1):90-100.
8. Neuzil J, Weber T, Gellert N, Weber C. Selective cancer cell killing by alpha-tocopheryl succinate. Br J Cancer 2001;84(1): 87-89.
9. McCormick DL, Rao KV. Chemoprevention of hormone-dependent prostate cancer in the Wistar-Unilever rat. Eur Urol 1999;35(5-6):464-467.
10. Fleshner N, Fair WR, Huryk R, Heston WD. Vitamin E inhibits the high-fat diet promoted growth of established human prostate LNCaP tumors in nude mice. J Urol 1999;161(5):1651-1654.
11. Venkateswaran V, Fleshner NE, Sugar LM, Klotz LH. Antioxidants block prostate cancer in lady transgenic mice. Cancer Res 2004;64(16):5891-5896.
12. Suh J, Payvandi F, Edelstein LC, Amenta PS, Zong WX, Gelinas C, et al. Mechanisms of constitutive NF-kappaB activation in human prostate cancer cells. Prostate 2002;52(3):183-200.
13. Huang S, Pettaway CA, Uehara H, Bucana CD, Fidler IJ. Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 2001;20(31):4188-4197.
14. Zerbini LF, Wang Y, Cho JY, Libermann TA. Constitutive activation of nuclear factor kappaB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer. Cancer Res 2003;63(9):2206-2215.
15. Kolenko V, Bloom T, Rayman P, Bukowski R, Hsi E, Finke J. Inhibition of NF-kappa B activity in human T lymphocytes induces caspase-dependent apoptosis without detectable activation of caspase-1 and -3. J Immunol 1999;163(2):590-598.
16. Suh J, Rabson AB. NF-kappaB activation in human prostate cancer: Important mediator or epiphenomenon? J Cell Biochem 2004;91(1):100-117.
17. Mukhopadhyay A, Bueso-Ramos C, Chatterjee D, Pantazis P, Aggarwal BB. Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines. Oncogene 2001;20(52):7597-7609.
18. Kim CH, Kim JH, Lee J, Ahn YS. Zinc-induced NF-kappaB inhibition can be modulated by changes in the intracellular metallothionein level. Toxicol Appl Pharmacol 2003;190(2): 189-196.
19. Ondrey FG, Dong G, Sunwoo J, Chen Z, Wolf JS, Crowl-Bancroft CV, et al. Constitutive activation of transcription factors NF-(kappa)B, AP-1, and NF-IL6 in human head and neck squamous cell carcinoma cell lines that express pro-inflammatory and proangiogenic cytokines. Mol Carcinog 1999;26(2):119-129.
20. Huang Q, Shen HM, Ong CN. Inhibitory effect of emodin on tumor invasion through suppression of activator protein-1 and nuclear factor-kappaB. Biochem Pharmacol 2004;68(2):361-371.
21. Bancroft CC, Chen Z, Yeh J, Sunwoo JB, Yeh NT, Jackson S, et al. Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-kappaB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines. Int J Cancer 2002;99(4): 538-548.
22. Aalinkeel R, Nair MP, Sufrin G, Mahajan SD, Chadha KC, Chawda RP, et al. Gene expression of angiogenic factors correlates with metastatic potential of prostate cancer cells. Cancer Res 2004;64(15):5311-5321.
23. Farina AR, Cappabianca L, Mackay AR, Tiberio A, Tacconelli A, Tessitore A, et al. Transcriptional regulation of intercellular adhesion molecule 1 by phorbol ester in human neuroblastoma cell line SK-N-SH involves jun- and fos-containing activator protein 1 site binding complex(es). Cell Growth Differ 1997; 8(7):789-800.
24. Catz SD, Johnson JL. Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostate cancer. Oncogene 2001;20(50):7342-7351.
25. Chung TD, Yu JJ, Spiotto MT, Bartkowski M, Simons JW. Characterization of the role of IL-6 in the progression of prostate cancer. Prostate 1999;38(3):199-207.
26. Palmer J, Ernst M, Hammacher A, Hertzog PJ. Constitutive activation of gp130 leads to neuroendocrine differentiation in vitro and in vivo. Prostate 2005;62(3):282-289.
27. Hu X, Janssen WE, Moscinski LC, Bryington M, Dangsupa A, Rezai-Zadeh N, et al. An IkappaBalpha inhibitor causes leukemia cell death through a p38 MAP kinase-dependent, NF-kappaB-independent mechanism. Cancer Res 2001;61(16): 6290-6296.
28. Bharti AC, Aggarwal BB. Nuclear factor-kappa B and cancer: Its role in prevention and therapy. Biochem Pharmacol 2002; 64(5-6):883-888.
29. Li-Weber M, Weigand MA, Giaisi M, Suss D, Treiber MK, Baumann S, et al. Vitamin E inhibits CD95 ligand expression and protects T cells from activation-induced cell death. J Clin Invest 2002;110(5):681-690.
30. Maziere C, Cortte MA, Degonville J, Ali D, Maziere JC. Cellular enrichment with polyunsaturated fatty acids induces an oxidative stress and activates the transcription factors AP1 and NFkappaB. Biochem Biophys Res Commun 1999;265(1):116-122.
31. Rocksen D, Ekstrand-Hammarstrom B, Johansson L, Bucht A. Vitamin E reduces transendothelial migration of neutrophils and prevents lung injury in endotoxin-induced airway inflammation. Am J Respir Cell Mol Biol 2003;28(2):199-207.
32. Yuspa SH. The pathogenesis of squamous cell cancer: Lessons learned from studies of skin carcinogenesis. J Dermatol Sci 1998;17(1):1-7.
33. Dalen H, Neuzil J. Alpha-tocopheryl succinate sensitises a T lymphoma cell line to TRAIL-induced apoptosis by suppressing NF-kappaB activation. Br J Cancer 2003;88(1):153-158.
34. Klein EA, Thompson IM, Lippman SM, Goodman PJ, Albanes D, Taylor PR, et al. SELECT: The selenium and vitamin E cancer prevention trial. Urol Oncol 2003;21(1):59-65.
35. Ni J, Chen M, Zhang Y, Li R, Huang J, Yeh S. Vitamin E succinate inhibits human prostate cancer cell growth via modulating cell cycle regulatory machinery. Biochem Biophys Res Commun 2003;300(2):357-363.
36. Zhang M, Altuwaijri S, Yeh S. RRR-alpha-tocopheryl succinate inhibits human prostate cancer cell invasiveness. Oncogene 2004;23(17):3080-3088.
37. Zu K, Ip C. Synergy between selenium and vitamin E in apoptosis induction is associated with activation of distinctive initiator caspases in human prostate cancer cells. Cancer Res 2003;63(20):6988-6995.
38. Gunawardena K, Campbell LD, Meikle AW. Combination therapy with vitamins C plus E inhibits survivin and human prostate cancer cell growth. Prostate 2004;59(3):319-327.
39. Zhang Y, Ni J, Messing EM, Chang E, Yang CR, Yeh S. Vitamin E succinate inhibits the function of androgen receptor and the expression of prostate-specific antigen in prostate cancer cells. Proc Natl Acad Sci USA 2002;99(11):7408-7413.
40. Quin J, Engle D, Litwiller A, Peralta E, Grasch A, Boley T, et al. Vitamin E succinate decreases lung cancer tumor growth in mice. J Surg Res 2005;127(2):139-143.
41. Lawson KA, Anderson K, Simmons-Menchaca M, Atkinson J, Sun L, Sanders BG, et al. Comparison of vitamin E derivatives alpha-TEA and VES in reduction of mouse mammary tumor burden and metastasis. Exp Biol Med (Maywood) 2004;229(9): 954-963.